GlassScriptPhysician profile
Krista S Silverman
NPI 1497912471
$4,016.18
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $1,646 · 2023: $1,299 · 2024: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $554.88 | 2021-2023 | Dalvance, Teflaro, Avycaz |
| Janssen Scientific Affairs, LLC | $424.76 | 2022-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $331.10 | 2023-2024 | Jynarque, Rexulti |
| Gilead Sciences, INC. | $284.16 | 2022 | |
| Medtronic, INC. | $273.02 | 2022-2023 | Linq II |
| Biohaven Pharmaceutical Holding Company LTD. | $272.69 | 2022 | |
| Novo Nordisk INC | $233.27 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.19 | 2021 | |
| Mylan Specialty L.P. | $186.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $148.92 | 2022-2023 | Eliquis |
| Pfizer INC. | $140.95 | 2023 | |
| Abbott Laboratories | $136.86 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $122.06 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.96 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.72 | 2022-2023 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $98.88 | 2021-2022 | |
| Exact Sciences Corporation | $96.65 | 2023 | Cologuard Collection Kit |
| Bioxcel Therapeutics, INC. | $85.63 | 2023 | Igalmi |
| Grifols USA, LLC | $61.76 | 2021-2023 | Prolastin-C Liquid |
| Dynavax Technologies Corporation | $37.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.67 | 2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.33 | 2022 | |
| Csl Behring | $14.23 | 2023 | Kcentra |
| Sanofi-Aventis U.S. LLC | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.